Table 4 Multivariate Cox-regression survival analysis in patients with ER pos. breast cancer

A

Variable

HR (95 % CI)

P

HR (95 % CI)

P

HR (95 % CI)

P

HR (95 % CI)

P

Size

T1 vs. T2/3/4

1.8 (1.3–2.5)

0.001

1.8 (1.3–2.5)

0.001

1.6 (1.2–2.1)

0.001

1.6 (1.2–2.2)

0.001

LN

neg. vs. pos.

1.9 (1.3–2.8)

0.001

2.0 (1.3–2.9)

0.001

1.6 (1.2–2.3)

0.002

1.7 (1.3–2.4)

0.001

Tumour grade

I vs. II vs. III

1.5 (1.2–2.0)

0.004

1.5 (1.1 -2.0)

0.006

1.3 (1.1 -1.7)

0.013

1.3 (1.0 -1.6)

0.024

MP

pre vs. post

1.4 (0.9–2.2)

0.094

1.3 (0.9–2.1)

0.177

1.9 (1.3–2.8)

0.001

1.7 (1.2–2.6)

0.006

HER2

neg. vs. pos.

1.5 (1.0–2.3)

0.074

1.5 (1.0–2.3)

0.058

1.4 (1.0–2.0)

0.084

1.4 (1.0–2.1)

0.062

Histology

1.0 (0.7–1.3)

0.870

1.0 (0.8–1.3)

0.981

1.0 (0.8–1.2)

0.987

1.0 (0.8–1.3)

0.876

Chemotherapy

no vs. yes

2.0 (1.2–3.4)

0.005

2.0 (1.2–3.4)

0.006

1.8 (1.1–2.9)

0.013

1.8 (1.1–2.9)

0.013

Radiation therapy

no vs. yes

1.0 (0.7–1.4)

0.994

1.0 (0.7–1.3)

0.832

0.9 (0.7–1.1)

0.242

0.8 (0.6–1.1)

0.141

Endocrine therapy

no vs. yes

0.7 (0.5–1.2)

0.192

0.8 (0.5–1.2)

0.297

0.8 (0.6–1.2)

0.237

0.9 (0.6–1.2)

0.392

NFE2L2 mRNA expression

low vs. high (< or > 65^th %ile)

-

-

0.6 (0.4–0.9)

0.008

-

-

0.6 (0.4–0.8)

0.001

B

Variable

HR (95 % CI)

P

HR (95 % CI)

P

HR (95 % CI)

P

HR (95 % CI)

P

Size

T1 vs. T2/3/4

2.6 (1.0–6.9)

0.056

2.9 (1.1–8.0)

0.038

1.8 (0.8–3.9)

0.152

1.9 (0.8–4.1)

0.128

LN

neg. vs. pos.

1.7 (0.7–4.6)

0.255

1.7 (0.6–4.6)

0.289

3.1 (1.3–7.3)

0.008

2.8 (1.2–6.5)

0.016

Tumour grade

I vs. II vs. III

0.9 (0.4–2.4)

0.908

1.6 (0.5–4.6)

0.403

0.6 (0.3–1.2)

0.122

0.7 (0.3–1.4)

0.313

MP

pre vs. post

0.6 (0.2–1.4)

0.221

0.5 (0.2–1.1)

0.086

1.1 (0.5–2.7)

0.756

1.1 (0.5–2.6)

0.778

HER2

neg. vs. pos.

0.4 (0.1–1.2)

0.107

0.4 (0.1–1.1)

0.079

0.7 (0.3–1.5)

0.338

0.7 (0.3–1.6)

0.420

Histology

1.5 (0.6–3.7)

0.375

1.1 (0.4–2.8)

0.895

2.1 (1.0–4.4)

0.039

2.2 (1.0–4.6)

0.045

Chemotherapy

no vs. yes

0.9 (0.3–2.2)

0.761

0.7 (0.3–1.8)

0.484

0.7 (0.3–1.6)

0.437

0.7 (0.3–1.5)

0.296

Radiation therapy

no vs. yes

1.7 (0.7–4.0)

0.250

1.5 (0.6–3.6)

0.349

0.7 (0.3–1.3)

0.209

0.7 (0.3–1.3)

0.211

Endocrine therapy

no vs. yes

0.9 (0.2–3.4)

0.879

1.4 (0.4–5.6)

0.616

1.0 (0.3–2.8)

0.986

1.1 (0.4–3.2)

0.823

NFE2L2 mRNA expression

low vs. high (< or > 65^th %ile)

-

-

0.2 (0.1–0.7)

0.012

-

-

0.5 (0.2–1.1)

0.072

low vs. high (< or > median)

-

-

0.2 (0.1–0.5)

0.001

-

-

0.4 (0.2–0.8)

0.009